JP6644685B2 - ポマリドミドの調製およびその精製のための改善された方法 - Google Patents

ポマリドミドの調製およびその精製のための改善された方法 Download PDF

Info

Publication number
JP6644685B2
JP6644685B2 JP2016534173A JP2016534173A JP6644685B2 JP 6644685 B2 JP6644685 B2 JP 6644685B2 JP 2016534173 A JP2016534173 A JP 2016534173A JP 2016534173 A JP2016534173 A JP 2016534173A JP 6644685 B2 JP6644685 B2 JP 6644685B2
Authority
JP
Japan
Prior art keywords
pomalidomide
group
solvent
dione
piperidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016534173A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017505286A (ja
JP2017505286A5 (enExample
Inventor
ゴア，ヴィナヤク
シュクラ，ヴィナイ・クマール
シンデ，ダナンジャイ
プラカシュ，バンソデ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mylan Laboratories Ltd
Original Assignee
Mylan Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mylan Laboratories Ltd filed Critical Mylan Laboratories Ltd
Priority claimed from IN5409CH2013 external-priority patent/IN2013CH05409A/en
Publication of JP2017505286A publication Critical patent/JP2017505286A/ja
Publication of JP2017505286A5 publication Critical patent/JP2017505286A5/ja
Application granted granted Critical
Publication of JP6644685B2 publication Critical patent/JP6644685B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2016534173A 2013-11-25 2014-11-24 ポマリドミドの調製およびその精製のための改善された方法 Expired - Fee Related JP6644685B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN5409/CHE/2013 2013-11-25
IN424/CHE/2014 2014-01-30
IN424CH2014 2014-01-30
IN5409CH2013 IN2013CH05409A (enExample) 2013-11-25 2014-11-24
PCT/IB2014/066285 WO2015075694A1 (en) 2013-11-25 2014-11-24 Improved process for the preparation of pomalidomide and its purification

Publications (3)

Publication Number Publication Date
JP2017505286A JP2017505286A (ja) 2017-02-16
JP2017505286A5 JP2017505286A5 (enExample) 2018-01-11
JP6644685B2 true JP6644685B2 (ja) 2020-02-12

Family

ID=52350154

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016534173A Expired - Fee Related JP6644685B2 (ja) 2013-11-25 2014-11-24 ポマリドミドの調製およびその精製のための改善された方法

Country Status (9)

Country Link
US (1) US20160362391A1 (enExample)
EP (1) EP3074383B1 (enExample)
JP (1) JP6644685B2 (enExample)
AU (1) AU2014351354B2 (enExample)
BR (1) BR112016011700B1 (enExample)
CA (1) CA2931606A1 (enExample)
ES (1) ES2694512T3 (enExample)
TR (1) TR201816539T4 (enExample)
WO (1) WO2015075694A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104557858B (zh) * 2013-10-29 2018-06-01 上海医药工业研究院 一种泊利度胺的制备方法
HU231259B1 (hu) 2016-02-04 2022-06-28 Egyt Gyogyszervegyeszeti Gyar Eljárás pomalidomide elõállítására
CN105924426B (zh) * 2016-06-20 2019-03-08 浙江海正药业股份有限公司 一种泊马度胺的结晶工艺
CN105866297B (zh) * 2016-06-24 2019-01-04 合肥久诺医药科技有限公司 一种泊马度胺有关物质的高效液相色谱分析方法
CN106565668B (zh) * 2016-10-27 2020-01-10 扬子江药业集团有限公司 一种高纯度泊马度胺的制备方法
WO2018154516A1 (en) * 2017-02-23 2018-08-30 Sun Pharmaceutical Industries Limited Process for the preparation of pomalidomide
CN114605381A (zh) * 2020-12-03 2022-06-10 南京海辰药业股份有限公司 一种泊马度胺的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6660736B2 (en) * 2002-03-27 2003-12-09 Hoffmann-La Roche Inc. Phthalimido derivatives and a process for their preparation
DK2380887T3 (da) * 2005-06-30 2013-10-07 Celgene Corp Fremgangsmåder til fremstilling af 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dion-forbindelser
US20120302605A1 (en) * 2010-11-18 2012-11-29 Deuteria Pharmaceuticals, Llc 3-deutero-pomalidomide
US20140221427A1 (en) * 2011-06-22 2014-08-07 Celgene Corporation Isotopologues of pomalidomide
WO2013126326A1 (en) * 2012-02-21 2013-08-29 Celgene Corporation Solid forms of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, compositions and methods of use thereof
WO2014170909A2 (en) * 2013-04-01 2014-10-23 Hetero Research Foundation Process for pomalidomide
CN103275062B (zh) * 2013-05-17 2016-04-13 宁波百思佳医药科技有限公司 一种Pomalidomide的纯化方法
CN103288797B (zh) * 2013-05-17 2016-03-02 宁波百思佳医药科技有限公司 一种用亚砜类溶剂纯化Pomalidomide的方法

Also Published As

Publication number Publication date
US20160362391A1 (en) 2016-12-15
JP2017505286A (ja) 2017-02-16
WO2015075694A1 (en) 2015-05-28
CA2931606A1 (en) 2015-05-28
EP3074383B1 (en) 2018-10-10
BR112016011700B1 (pt) 2022-08-23
ES2694512T3 (es) 2018-12-21
BR112016011700A2 (pt) 2017-10-10
AU2014351354B2 (en) 2018-11-08
AU2014351354A1 (en) 2016-06-16
EP3074383A1 (en) 2016-10-05
TR201816539T4 (tr) 2018-11-21

Similar Documents

Publication Publication Date Title
JP6644685B2 (ja) ポマリドミドの調製およびその精製のための改善された方法
JP5064024B2 (ja) イマチニブの製造方法、及び該方法により製造されたイマチニブ
AU2002344419B2 (en) Alpha-form or beta-form cyrstal of acetanilide derivative
JP5701246B2 (ja) 有機化合物
WO2009114601A2 (en) Preparation of lenalidomide
JP7761578B2 (ja) シクロスポリン誘導体の調製
JP2009537603A (ja) ５−アミノ−３−（２’，３’−ジ−Ｏ−アセチル−ベータ−Ｄ−リボフラノシル）−３Ｈ−チアゾロ［４，５−ｄ］ピリミジン−２−オンのマレイン酸塩のＡ型及びＢ型結晶形
FI110096B (fi) Menetelmä terapeuttisesti käyttökelpoisen kiteisen Tiagabine-hydrokloridimonohydraatin valmistamiseksi
WO2015177758A1 (en) Novel polymorphs of cabozantinib (s)-malate and cabozantinib free base
JP4917440B2 (ja) Ｇａｂａａアゴニストの多形性形態
WO2011033307A1 (en) Nilotinib dihydrochloride salt
WO2010056384A1 (en) Lenalidomide solvates and processes
EP2321258A1 (en) Polymorphic form of rasagiline mesylate
WO2017049992A1 (zh) Egfr激酶抑制剂及其制备方法和应用
CN107530349A (zh) 作为a2b拮抗剂的黄嘌呤取代的炔基氨基甲酸酯/反式氨基甲酸酯
EP3360858A1 (en) Process for producing an aminopyrrolidine derivative
EP2450343A1 (en) Method for producing threo-3-(3,4-dihydroxyphenyl)-l-serine
WO2016038560A1 (en) Process for the preparation of enzalutamide
JP2022515610A (ja) ｅｘｏ－ｔｅｒｔ－ブチルＮ－（３－アザビシクロ［３．２．１］オクタン－８－イル）カルバミン酸塩の調製のためのプロセス
US20240239791A1 (en) Processes for the synthesis of valbenazine
RU2741389C1 (ru) Способ получения промежуточного соединения для синтеза лекарственного средства
CN118324750A (zh) 三嗪衍生物富马酸共晶的制备方法
JP2012500276A (ja) グラニセトロン塩酸塩の多形体とその製造方法
WO2016038590A1 (en) Process for the preparation of crystalline form i of regorafenib
HK1165787A (en) Method for producing threo-3-(3,4-dihydroxyphenyl)-l-serine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180803

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190822

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191213

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200108

R150 Certificate of patent or registration of utility model

Ref document number: 6644685

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees